Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)

Completed · Phase 2

Conditions studied: Respiratory Syncytial Virus Infections

In brief

To evaluate the safety,tolerability and antiviral activitity of ALN-RSV01 in RSV infected lung transplant patients

Key facts

Study ID

NCT00658086

Run by

Alnylam Pharmaceuticals

People needed

24

Starts

2008-04-01

Expected to finish

2009-06-01

Last updated by the study team

2018-01-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Single or bilateral lung transplant recipients
• Confirmed RSV infection
• Greater than 90 days post current lung transplant
• Rejection free for a minimum of 1 month

You may not qualify if…

• Antimicrobial therapy for known viral, bacterial, or fungal respiratory co-infection at the time of diagnosis
• Bronchiolitis obliterans syndrome (BOS) Grade 3 or any state BOS with FEV1 that has not been stable for at least 3 months
• Use of alemtuzumab within 9 months prior to screening; anti-thymocyte globulin(ATG) or thymoglobulin within 3 months of screening: concurrent use of >= 0.3 mg/kg/day prednisone or equivalent as maintenance therapy
• active treament for acute graft rejection

Where it is running

• Clinical Site — San Diego, California, United States
• Clinical Site — San Francisco, California, United States
• Clinical Site — Denver, Colorado, United States
• Clinical Site — Gainesville, Florida, United States
• Clinical Site — Atlanta, Georgia, United States
• Clinical Site — Chicago, Illinois, United States
• Clinical Site — Boston, Massachusetts, United States
• Clinical Site — Minneapolis, Minnesota, United States
• Clinical Site — Cleveland, Ohio, United States
• Clinical Site — Nashville, Tennessee, United States
• Clinical Site — Sydney, New South Wales, Australia
• Clinical Site — Brisbane, Queensland, Australia
• Clinical Site — Perth, Western Australia, Australia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.